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Melanoma cells can switch phenotype in a manner similar to epithelial to mesenchymal
transition (EMT). In this perspective article, we address the effects of such phenotype
switching on T cell targeting of tumor cells. During the EMT-like switch in phenotype,
a concomitant change in expression of multiple tumor antigens occurs. Melanoma cells
undergoing EMT escape from killing by T cells specific for antigens whose expression
is downregulated by this process. We discuss melanoma antigens whose expression is
influenced by EMT. We assess the effect of changes in the expressed tumor antigen reper-
toire on T-cell mediated tumor recognition and killing. In addition to escape from T cell
immunity via changes in antigen expression, mesenchymal-like melanoma cells are gener-
ally more resistant to classical chemotherapy and radiotherapy. However, we demonstrate
that when targeting antigens whose expression is unaltered during EMT, the capacity of
T cells to kill melanoma cell lines in vitro is not influenced by their phenotype. When con-
sidering immune therapies such as cancer vaccination, these data suggest escape from T
cell killing due to phenotype switching in melanoma could potentially be avoided by careful
selection of target antigen.
Keywords: T-lymphocytes, melanoma, epithelial–mesenchymal transition, tumor antigens, T cell killing, cancer
testis antigens
INTRODUCTION
The ability of melanoma cells to switch phenotype from prolif-
erative to more invasive states, in a process similar to classical
epithelial-mesenchymal transition (EMT), has been well described
(1). Non-motile, polarized, and proliferative epithelial-like (E-
like) cells, acquire motile, fibroblast-like mesenchymal characteris-
tics (2). The process contributes to the heterogeneity of the tumor,
and may be a factor in disease progression (3, 4). In melanoma,
the EMT-like switch in phenotype can be driven by environmen-
tal pressures such as changes in the cytokine milieu at the tumor
site, e.g., due to inflammation (5), and drug treatments such as
inhibition of oncogenic BRAF (6).
We have previously generated a panel of 57 melanoma cell
lines derived from patient samples (7). We have characterized
these cell lines as E-like or mesenchymal-like (M-like) on the
basis of expression levels of E-cadherin or N-cadherin, respec-
tively (8). Between these two cohorts, we documented significant
disparity in gene expression levels of many mRNA, reflective of
the functional and phenotypic differences between the groups.
Included in these differentially expressed genes, were mRNAs
encoding melanocytic differentiation proteins, such as Melan-A
and tyrosinase. Both of these have demonstrated antigenic epi-
topes,which have been previously used as targets of cancer vaccines
in melanoma clinical trials (9–11), and are currently the tar-
get antigens in ongoing trials (NCT01331915, NCT01748747).
Expression of these genes, as well as the master regulator of
differentiation, MITF (Microphthalmia-associated transcription
factor), was significantly downregulated in M-like cell lines com-
pared to E-like (8). A decrease in expression of the melanoma
differentiation antigens (MDA) under the control of MITF during
EMT has also been reported by others, e.g., gp100.
The cancer testis group of antigens (CTAg) have been identi-
fied as important immune targets in melanoma, as well as other
cancer types, and have been studied extensively (12, 13). Expres-
sion of CT genes is generally restricted to immune-privileged body
sites, yet is frequently and selectively re-activated in a broad vari-
ety of human cancers (12). Almost 150 families have been defined
(http://www.cta.lncc.br) (14). Their immunogenicity and selective
expression in cancer makes them attractive targets for therapeu-
tic cancer vaccines, and many have been used for this purpose
over the past ~2 decades, with limited success (15). In parallel
with EMT-associated downregulation of certain melanoma anti-
gens, particularly the differentiation antigens, which are under the
control of MITF, we have also observed upregulation in expres-
sion of a number of cancer testis antigens (CTAg). In particular,
we showed that expression of the SPANX family of CTAg was
enhanced in M-like compared to E-like cell lines (8). This group
of CTAg has documented immunogenicity (16) and their expres-
sion is found at higher levels in more aggressive tumors (17). A
range of CTAg (including SPANX and a number of MAGE family
members) were also recently shown to be upregulated following
EMT in a colorectal cancer cell line (18).
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Independent of the well-documented functional differences
between E- and M-like cells, the changes in expression of
immunogenic antigens between melanoma phenotypic subsets
has profound implications for immune-based recognition and
clearance of tumor. For example, based on our studies, immune
responses induced against antigens such as Melan-A and tyrosi-
nase would potentially only be effective in clearing differentiated
E-like tumor cells. Indeed, a previous study highlighted the EMT-
like phenotypic switch in melanoma as a method of escape from
adoptive T cell therapy with T-lymphocytes targeting Melan-
A (19). This study also showed that M-like cells were poorly
recognized by T-lymphocytes that were specific for melanocytic
antigens, whereas recognition by T-lymphocytes specific for non-
melanocytic antigens was unaffected or even increased in vivo.
Taken together, the studies discussed here highlight the dis-
parity of the immunogenic profile of E-like versus M-like tumor
cells, and emphasize the importance of appropriate target antigen
selection for cancer vaccine/T cell targeting approaches.
The M-like phenotype has been associated with tumor progres-
sion, invasion, and metastasis in melanoma (20, 21). This generally
more aggressive phenotype is accompanied by acquisition of resis-
tance to drug treatment and radiotherapy (22). Furthermore, this
phenotype also emerges after the development of resistance against
BRAF inhibitors (6). Thus, M-like cells are generally considered
more difficult to eradicate, by multiple mechanisms, compared
with their E-like counterparts.
In this article, we ask whether M-like melanoma cells are inher-
ently resistant to killing by T-lymphocytes at a functional level,
reflective of the mesenchymal state, or whether an escape from
T cell-mediated killing via phenotype switching is simply reflec-
tive of the decrease in expression of many target tumor antigens.
We show that expression of the prototypic cancer testis antigen
NY-ESO-1 is unaltered between melanoma phenotypic states. We
compare the ability of NY-ESO-1 or Melan-A specific T cell clones
to recognize and kill melanoma cell lines, which were phenotypi-
cally either E-like or switched to M-like following incubation with
TGFβ (23).
MATERIALS AND METHODS
MELANOMA CELL LINES AND CULTURE
Establishment and characterization of the melanoma cell lines
used has been previously described (7). Cells were cultured in
RPMI 1640, 2 mM Glutamax, 100 IU/ml Penicillin, 100µg/ml
Streptomycin, and 10% fetal calf serum (RF10) (all Invitrogen). To
induce EMT, subconfluent cell lines were incubated with 5 ng/ml
TGF-beta 1 (Pepro Tech) for 72 h.
GENE EXPRESSION ARRAY
The gene expression array method and analysis have been previ-
ously described (24). Briefly, genomic DNA was purified from
melanoma cell lines (Qiagen AllPrep kits) and assayed using
Illumina standard protocols.
QUANTITATIVE REAL-TIME POLYMERASE CELL REACTION (QRT-PCR)
cDNA was generated using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Quantitative poly-
merase chain reaction (qPCR) was performed using the Quan-
tiFast SYBR Green PCR Kit (Qiagen). Primer sequences were
as follows: NY-ESO-1 (forward) 5′-gagccgcctgcttgagtt-3′ and
(reverse) 5′-agcactgcgtgatccacatc-3′; Melan-A (forward) 5′-gaga
aaaactgtgaacctgtggt-3′ and (reverse) 5′-gactgttctgcagagagtttctcat-
3′; N-cadherin (forward) 5′-ctccatgtgccggatagc-3′ and (reverse)
5′-cgatttcaccagaagcctctac-3′ β-actin (forward) 5′-ctggaacggtgaagg
tgaca-3′ and (reverse) 5′-cggccacattgtgaactttg-3′.
IMMUNOFLUORESCENCE
Melanoma cell lines were treated with 5 ng/ml TGF-β1 for 72 h and
fixed with 4% paraformaldehyde. Mouse anti-E-cadherin anti-
body (HECD1, Invitrogen) and rabbit anti-N-cadherin antibody
(AB18203, Abcam) were applied at 2 and 1µg/ml concentration,
respectively, overnight at 4°C. Cells were subsequently treated with
Alexa flour 488 (anti-mouse) and 555 (anti-rabbit) conjugated
secondary antibodies for 45 min at room temperature (Molecular
probes, USA). Cells were counter stained with DAPI for 10 min.
GENERATION OF ANTIGEN SPECIFIC CD8+ T CELL CLONES
CD8+ T cell clones specific for the NY-ESO-1 HLA-A*0201
restricted peptide 157–165,or the Melan-A HLA-A*0201 restricted
peptide 26–35, were generated from patients who consented to
participate in our cancer research protocol (approved by Austin
Health Human Research Ethics Committee). PBMC (peripheral
blood mononuclear cells) were stimulated with 1× 10−6 M pep-
tide, then cultured for 10 days in the presence of 25 IU/ml IL-2
(Miltenyi biotech). Specific cells were labeled with a fluorescent
tetramer, comprising the relevant peptide and HLA (TCMetrix)
and single-cell sorted using a MoFlow cytometer. Clones were
expanded with pooled, autologous healthy donor PBMC as feeder
cells, PHA-L (Sigma), and 600 IU/ml IL-2. After approximately
20 days, 1–10× 103 clones were restimulated in the presence of
autologous PBMC as feeder cells, PHA-L, and 600 IU/ml IL-2,
as described above. Clone specificity was confirmed by tetramer
staining.
T cell clones/lines were cultured in RPMI 1640 media
supplemented with 20 mM N -2-hydroxyethylpiperazine-N ’-2-
ethanesulfonic acid, 60 mg/L penicillin, 12.5 mg/L streptomycin,
2 mM l-glutamine, 1% non-essential amino acids, and 10%
human serum (TCRPMI).
T CELL KILLING ASSAYS
Twenty thousand melanoma cells were plated in wells of a flat
bottom 96-well plate. T cells were added to selected wells as appro-
priate to give the effector to target (E:T) ratios shown in the
text. Samples were incubated overnight (~16–24 h) at 37°C. The
following day, T cells were resuspended by gentle pipetting and
then removed. The plate was washed once with PBS. MTS reagent
(CellTiter 96® AQueous One Solution Cell, Promega) was added
and samples incubated for 1–2 h at 37°C. Absorbance at 490 nm
was measured, and normalized to melanoma samples incubated in
absence of T cells for each cell line to give percentage of viable cells.
RESULTS
We assessed gene expression in our panel of 57 early passage
melanoma cell lines (7, 24). Cell lines were classified as E-like
or M-like on the basis of E-cadherin or N-cadherin expression,
respectively. We have previously reported widespread variation in
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antigen expression between E- or M-like phenotypes (8). Here, we
focus on the difference in expression of a range of immunogenic
antigens, including MDA and CTAg, shown in Figure 1. As previ-
ously reported by ourselves and others, expression of MDA (e.g.,
Melan-A and tyrosinase) and MITF was largely lower in M-like,
compared to E-like, cells. In contrast, a number of CTAg (e.g.,
SPANX family members) were upregulated in M-like cells. The
expression of some antigens (e.g., MAGED1) was unaffected by
the differences in phenotype between our cell lines. These data
highlight the immunogenic heterogeneity of melanoma.
Based on our previous studies (7, 8), we selected four E-like
melanoma cell lines, which were HLA-A*0201+, and which were
also positive for expression of either Melan-A, or NY-ESO-1, or
both. As a control, we also obtained an M-like cell line (LM-
Mel 53). The selected lines were treated with TGFβ for 72 h to
induce EMT, and successful switch to an M-like phenotype was
confirmed by demonstrating upregulation of N-cadherin gene
expression by qPCR, or protein expression by immunofluores-
cence (Figures 2A,B). In all four E-like cell lines, upregulation of
N-cadherin expression was observed following TGFβ incubation,
FIGURE 1 |Tumor antigen expression in melanoma epithelial or
mesenchymal-like cell lines. Microarray-based gene expression of a range
of melanoma antigens, including several melanoma differentiation antigens
and cancer-testis antigens across a panel of 57 early passage melanoma cell
lines and 2 controls (normal melanocytes; “melanocyte” and neonatal
melanocytes; “neonatal”). Melanoma cell lines were classified as
epithelial-like (top bar; red) or mesenchymal-like (top bar; blue) on the basis of
dominant E-cadherin or N-cadherin expression, respectively, however,
unsupervised clustering of the cell lines was performed without reference to
this annotation. Control melanocytes have been labeled in black.
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FIGURE 2 | Antigen expression andT cell-mediated lysis of melanoma
cell lines followingTGFβ induced EMT. Epithelial-like melanoma cells
lines, LM Mel 1a, LM Mel 28, SK Mel 8, and LM Mel 34, and
mesenchymal-like cell line LM Mel 53, were incubated with 5 ng/ml TGFβ
for 72 h to induce EMT. Cells were lysed, and cDNA was generated (as in
Section “Materials and Methods”). (A) Expression levels of N-cadherin in
treated and untreated cell lines were determined by qPCR, in order to
assess switching to the mesenchymal-like phenotype, and expressed
relative to 10,000 copies of β-actin. (B) Immunofluorescence confirmed
increase in N-cadherin protein expression (Red) and concomitant reduction
in E-cadherin (Green) after 72 h of TGF-β1 treatment, shown here for a
representative cell line (LM-Mel 28). Scale bar=100µM. Expression levels
of (C) Melan-A and (D) NY-ESO-1 were compared between TGFβ
treated/untreated melanoma cell lines expressing these antigens.
Melanoma cell lines expressing Melan-A, and/or NY-ESO-1 were treated
with/without 5 ng/ml TGFβ for 72 h. Specific T cell clones, which
recognized the HLA-A*0201 epitopes (E) Melan-A 26–35 or (F) NY-ESO-1
157–165 were incubated with 2×104 treated/untreated melanoma cells at
a 1:1 effector to target ratio. Cells were incubated for 24 h at 37°C. T cells
were washed off, followed by addition of MTS reagent (Promega) and 1 h
incubation at 37°C. Absorbance was read at 490 nm, and normalized to
untreated control cells for each treatment condition. Each measurement
was in triplicate, and treated/untreated samples were compared using a
pairedT-test. ns=not significant. **P ≤0.01.
whereas there was no significant change in N-cadherin expression
by the M-like cell line.
Epithelial-like cell lines LM-Mel 1a, LM-Mel 28, and LM-
Mel 34 express Melan-A under steady state conditions, while
the M-like cell line LM-Mel 53 expresses low levels of this
antigen. In our heatmap (Figure 1), no cell line demonstrated
expression of NY-ESO-1/CTAG1B, which is likely due to inef-
ficiency of the probe (probes to CTAg are traditionally infe-
rior), since we have shown by qPCR (Figure 2D) and IHC
(not shown) that several of our cell lines express NY-ESO-1.
The effect of phenotypic switching by EMT on the expression
of either Melan-A or NY-ESO-1 was assessed in the relevant
cell lines. qPCR demonstrated that while gene expression lev-
els of NY-ESO-1 did not alter significantly following EMT, the
expression levels of Melan-A decreased in all E-like, but not
M-like cell lines expressing this antigen (Figures 2C,D). This
result is in line with previous studies from our group and others,
which demonstrated downregulation of several MDA including
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Melan-A and related antigens under the transcriptional control
of MITF.
Previous studies have shown that TGFβ treatment results in
downregulation of MHC class II molecules, such as HLA-DR; how-
ever, no significant effect of TGFβ treatment on HLA class I levels
has been demonstrated (25). We assessed HLA Class I expression in
our cell lines before and after 72 h TGFβ treatment, and confirmed
that no significant change in HLA Class I levels occurred (data not
shown). This result is important for our subsequent experiments,
which assess T cell killing of TGFβ-treated/untreated melanoma
cell lines. In these studies, we can confirm that HLA does not play
a limiting role for either melanoma phenotype.
Since M-like cells are generally more resistant to various treat-
ment modalities, we tested whether T cell-mediated lysis of these
cells was also impeded. T cells, which recognized the HLA-A*0201
restricted epitope 157–165 from NY-ESO-1 or 26–35 from Melan-
A were incubated with melanoma cell lines expressing their respec-
tive target antigen, at a 1:1 effector:target ratio. Cells were incu-
bated for 24 h before viability of melanoma cells was assessed using
an MTS assay (methods), and normalized to untreated control cells
(Figures 2E,F). In all cell lines tested, NY-ESO-1 specific T cells
killed melanoma cell lines comparably both before and after TGFβ
treatment. In contrast, Melan-A specific T cells were significantly
more effective at killing E-like melanoma cells prior to induction
of EMT. Following TGFβ treatment, cell lines were less efficiently
cleared by Melan-A specific T cells in all cases tested.
Our results indicate that the ability of M-like cells to escape
from T cell-meditated lysis was not due to any inherent functional
characteristic of these cells, but rather due to changes in expres-
sion of target antigen. Melan-A expression decreased following
EMT, leading to corresponding diminishing ability of antigen spe-
cific T-lymphocytes to kill target cells. In contrast, the expression
of NY-ESO-1 was unchanged following EMT, and in parallel the
ability of specific T cells to recognize and kill melanoma cells in
an antigen specific manner was unaffected.
DISCUSSION
Contemporary melanoma therapy is undergoing a revolution due
to the unprecedented success of immune checkpoint inhibitors;
agents that re-activate anti-cancer immunity within treated
patients (26). These successes are a culmination of what scien-
tific researchers have long striven to achieve using methods such
as cancer vaccination and adoptive cell transfer, that is, appropriate
immune targeting in a manner which results in tumor clearance.
Phenotype switching by melanoma cells to an M-like phenotype
has been considered an inherent mechanism of tumor escape from
therapy and resistance to various treatment modalities. Set against
the back drop of recent immune-based treatment successes, we
find here that immune-mediated clearance of melanoma cells is
unaffected by EMT under the appropriate settings.
Previous treatment strategies have been hampered by the het-
erogeneity of the disease – escape of residual cells from radio-
therapy, emergence of resistance to BRAF inhibition, etc – and
a strategy which could target the tumor as a whole has eluded
researchers. Patients successfully treated by immune checkpoint
inhibition can continue to remain disease free long-term [4 years
at the most recent follow up for anti-CTLA4 therapy (27), and
~25 months for anti-PD-1 treatment (28)]. It is therefore clear that
appropriate immune control can achieve clearance of melanoma.
Despite the relative success of immune checkpoint inhibition,
many patients are still not rendered disease free with these agents.
In this cohort, rational combination therapies are likely to be ben-
eficial and extensive studies are currently underway to ascertain
which kinds of combination will exert broadest patient benefit and
disease control. These combination therapies will include target-
ing melanoma specific antigens by cancer vaccination or adoptive
cell therapy, in conjunction with immune checkpoint inhibition,
and indeed this is the focus of several current clinical trials
(NCT01176474, NCT02077114, NCT01176461, NCT01988077,
NCT01701674), including our own trial combining vaccination
with NY-ESO-1 and ipilimumab (NCT01810016).
Our study here, and others (8, 19, 29) highlight not only func-
tional but also immune heterogeneity of melanoma cells. We
demonstrate that EMT in melanoma can result in escape from
T cell targeting. Importantly, we have shown that the means of
tumor escape from immune-mediated killing is not due to an
intrinsic functional resistance mechanism of cells that display the
M-like phenotype, but rather is due to decrease in the expression
of target antigen. T lymphocyte targeting of selected antigens with
constant expression during EMT results in comparable killing of
melanoma cells in vitro independent of their phenotype. Since
M-like cells have traditionally been considered more difficult to
kill than their E-like counterparts, this finding is significant. The
ability of M-like and E-like tumor cells to be equally killed by
T cells recognizing appropriate targets confirms the potential of
combination treatments using appropriately selected antigens as
targets.
These data further highlight the importance of antigen selec-
tion for cancer vaccination or adoptive cell transfer, since even
if completely effective, therapeutic options which target antigens
preferentially expressed by E-like cells will be incapable of clear-
ing the tumor as a whole. Indeed such therapies could potentially
exert selective pressure for tumor cells with the more aggressive M-
like phenotype and thereby promote cell populations that carry a
poorer prognosis for the patient.
To develop this rationale further, antigen specific immunother-
apy strategies should ideally target antigens which are not only
expressed in differentiated E-like cells, but also those which are
either induced when the phenotype changes during EMT, or which
are consistently expressed in both E-like and M-like cells. The
former have been little examined in melanoma to date, most stud-
ies focusing on antigen loss leading to immune escape during
EMT. However, Figure 1 demonstrates that a subset of MAGE
antigens and the SPANX family of CTAgs are upregulated in M-
like melanoma cell lines. Furthermore, Boisgerault et al. demon-
strated that in prostate cancer, topoisomerase IIα and CD44 are
antigens which are specific to M-like cells, and further showed
that a subset of melanoma cells also expressed topoisomerase
IIα (29, 30).
Hopefully, combination treatment strategies with appropriately
selected target antigens as discussed here will result in enhanced
tumor clearance irrespective of tumor heterogeneity. Indeed, we
are currently assessing the efficacy of this approach using the
CTAgs SPANX, expression of which is induced during EMT,
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and Ropporin, whose expression in melanoma is widespread and
constant during EMT (manuscript in preparation).
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